Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Clinical efficacy of CAR-T cells depends on chemical modifications, says study

One in five cancers affects lymph nodes and blood cells resulting in lymphomas and leukemias, respectively.

7 Oct 2021

Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021

Study reveals how two separate DNA changes may predict aggressive childhood leukemias

New research published today in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination.

20 Aug 2021

Researchers develop method to preserve high-quality cultured stem cells for a long time

Hematopoietic stem cells — the precursors to blood cells — have been notoriously difficult to grow in a dish, a critical tool in basic research.

16 Aug 2021

Study: Biomarker can predict response to immunotherapies in breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

28 Jul 2021

Nanobody mapping using NMR proves a promising alternative for therapeutic use

Researchers used NMR techniques to determine the structure of a nanobody, facilitating a better understanding of how the protein fights against diseases.

6 Jul 2021

Cancer cells re-organize DNA structure to ramp up the activity of oncogenes

A lot of biological mechanisms go wrong in cancer—for example genes mutate and cells proliferate in an uncontrollable manner.

11 May 2021

Small molecular changes can have dramatic impact on the CAR T cell function

When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.

23 Apr 2021

Low representation of minority groups in genomic databases may impact therapy selection

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

22 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Research links blood-clotting protein with CNS B-cell lymphoma growth

In people with central nervous system (CNS) lymphoma, cancerous B cells--a type of white blood cell--accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.

18 Feb 2021

Tumor microenvironment could improve cancer immunotherapy

A study has revealed how chemicals surrounding tumors, the tumor microenvironment, undermine the immune system and allow cancer to resist attack.

16 Feb 2021

New understanding of tumor microenvironment could help enhance immunotherapy

A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.

16 Feb 2021

Researchers discover new molecular mechanism that promotes cell migration

Research groups at the University of Helsinki and Institut Jacques Monod, Paris, discovered a new molecular mechanism that promotes cell migration. The discovery sheds light on the mechanisms that drive the uncontrolled movement of cancer cells and also revises the 'textbook view' of cell migration.

10 Feb 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Scientists find new way to prevent cancer relapse after immunotherapy

Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed at?

18 Dec 2020

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

8 Dec 2020

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

8 Dec 2020

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

Lymphoma News and Research

Clinical efficacy of CAR-T cells depends on chemical modifications, says study

Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

Study reveals how two separate DNA changes may predict aggressive childhood leukemias

Researchers develop method to preserve high-quality cultured stem cells for a long time

Study: Biomarker can predict response to immunotherapies in breast cancer patients

Nanobody mapping using NMR proves a promising alternative for therapeutic use

Cancer cells re-organize DNA structure to ramp up the activity of oncogenes

Small molecular changes can have dramatic impact on the CAR T cell function

Low representation of minority groups in genomic databases may impact therapy selection

Engineered safety switch reduces CAR-T immunotherapy-related side effects

Research links blood-clotting protein with CNS B-cell lymphoma growth

Tumor microenvironment could improve cancer immunotherapy

New understanding of tumor microenvironment could help enhance immunotherapy

Researchers discover new molecular mechanism that promotes cell migration

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

Scientists find new way to prevent cancer relapse after immunotherapy

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

'Switching on' Sight using Gene Therapy

Digital Drone: New Technology to Improve Crop Yields

Does the Future of Farming Involve the Gene Editing of Farm Animals?

Latest Life Science News